General Pre-Trial Screening Protocol for Infectious Diseases Research

NCT ID: NCT06463704

Last Updated: 2024-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-21

Study Completion Date

2034-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) or Division of Infectious Diseases at Beth Israel Deaconess Medical Center. This general screening protocol will help to determine the eligibility of potential volunteers for any vaccine or therapeutic trials open for recruitment or soon to be opened.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) and Division of Infectious Diseases at Beth Israel Deaconess Medical Center. This protocol will help us to determine whether a volunteer is eligible for completing the screening process and which protocols might best be suited to the participant.

Volunteers will be adults interested in participating in a clinical trial, such as a vaccine or therapeutic study, and particularly for studies conducted as part of the HIV Vaccine Trials Network. Occasionally, the screening protocol may be used for an observational study. This general screening protocol will help to determine the eligibility of potential volunteers for any clinical trials open for recruitment or soon to be opened. No investigational products will be administered under this protocol. All main vaccine or intervention studies will be submitted as separate applications to the appropriate regulatory agency as required by the sponsor.

Prescreening of volunteers may be done via telephone using an already approved script and RedCap questionnaire. Following the prescreening, the volunteer will be scheduled for an in-person clinic visit with a study clinician (MD, NP or RN). All participants in this study will be screened for safety, including a physical exam, vital signs and laboratory testing. This is to ensure that participants meet the appropriate inclusion and exclusion criteria related to safety in a clinical trial. The following study procedures will be performed at the Clinical Research Center at BIDMC:

1. Informed Consent process completed before any other study activities are conducted
2. Demographics
3. Medical history
4. Review of current medications
5. Targeted physical exam including vital signs
6. Behavioral risk assessment to determine risk of acquiring HIV
7. Contraception status
8. Blood or urine collection: on average, most safety screening laboratory tests will require no more than 60mL of blood which will be resulted in BIDMC's clinical laboratory. A urine sample may be collected for people of childbearing potential to determine pregnancy status.

Laboratory tests will be checked against eligibility criteria of open or soon-to-be opened clinical trials. If a test or exam result suggest that further medical evaluation or treatment may be necessary, the participant will be notified and referred to their care provider for further treatment. A copy of test results will be provided if requested.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational cohort for potential study volunteers

This is a general screening protocol to develop a registry of potential volunteers for our clinical trials. There is no intervention to be administered.

There is no intervention

Intervention Type OTHER

There is no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

There is no intervention

There is no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older at time of consent
* Available to participate for the planned duration of the clinical trials for which screening is being done
* Capable of giving signed informed consent

Exclusion Criteria

• A condition, based on clinical judgement, which requires active medical intervention or monitoring to avert serious danger to the participant's health or well-being
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kathryn Stephenson

Associate Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kathryn E Stephenson, MD, MPH

Role: CONTACT

617-735-4556

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kathryn Stephenson, MD, MPH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023P000266

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.